Regulators Have Ways To Address Drug Affordability, EMA Officials Say
This article was originally published in The Pink Sheet Daily
Executive Summary
Regulators can contribute to sustainable drug pricing by approving biosimilars quickly, encouraging drug trials that measure value and taking other actions, European Medicines Agency officials say in an op-ed published in the New England Journal of Medicine.
You may also be interested in...
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.